ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes... Show more
ATAI is expected to report earnings to fall 62.57% to -10 cents per share on March 26
Q4'25
Est.
$-0.10
Q3'25
Missed
by $0.17
Q2'25
Missed
by $0.02
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.09
The last earnings report on November 12 showed earnings per share of -28 cents, missing the estimate of -10 cents. With 4.59M shares outstanding, the current market capitalization sits at 1.50B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ATAI showed earnings on November 12, 2025. You can read more about the earnings report here.